ACM
BTAI icon

Aquatic Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Aquatic Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-625
Closed -$118K – 1386
2022
Q3 		$118K Buy
625
+431
+222% +$100K 0.01% 721
2022
Q2 		$41K Buy
+194
New +$40.8K 0.01% 692
2022
Q1 		– Sell
-81
Closed -$26K – 1117
2021
Q4 		$26K Buy
+81
New +$34.8K 0.05% 511

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Aquatic Capital Management's BTAI Position: Q4 2022 in Review

Aquatic Capital Management sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 625 shares — an estimated $118K sold.

Aquatic Capital Management first reported a position in BTAI in Q4 2021 and held it in 3 quarters. The position peaked at $118K in Q3 2022. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

  • Aquatic Capital Management reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 625 BioXcel Therapeutics shares in Q4 2022, an estimated $118K.
  • Aquatic Capital Management first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 3 quarters.
  • Aquatic Capital Management's BioXcel Therapeutics position peaked at $118K in Q3 2022.
  • 83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on Aquatic Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.